EUVIMEDEUVIMED entdecken
Open Access

Effects of CYP3A4 and CYP2C9 Genotype on Systemic Anastrozole and Fulvestrant Concentrations in SWOG S0226

Delaney V Rutherford iD, Sarah Medley iD, Nicholas C Henderson iD, Christina L Gersch iD, Ted A Vandenberg iD, Kathy S Albain iD, Shaker R Dakhil iD, Nagendra R Tirumali, Julie R Gralow iD, Gabriel N Hortobagyi iD, Lajos Pusztai iD, Rita S Mehta und 6 weitere

Pharmacogenomics · 2023

DOI: 10.2217/pgs-2023-0097 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacogenomics, 2023. Verfasst von Delaney V Rutherford und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, MI 48109, USA. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A, Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NCI NIH HHS, American Association of Colleges of Pharmacy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective & methods: This study tested associations of genotype-predicted activity of CYP3A4, other pharmacogenes, SLC28A7 (rs11648166) and ALPPL2 (rs28845026) with systemic concentrations of the endocrine therapies anastrozole and fulvestrant in SWOG S0226 trial participants.

Results

Participants in the anastrozole-only arm with low CYP3A4 activity (i.e. CYP3A4*22 carriers) had higher systemic anastrozole concentrations than patients with high CYP3A4 activity (β-coefficient = 10.03; 95% CI: 1.42, 18.6; p = 0.025). In an exploratory analysis, participants with low CYP2C9 activity had lower anastrozole concentrations and higher fulvestrant concentrations than participants with high CYP2C9 activity.

Conclusion

Inherited genetic variation in CYP3A4 and CYP2C9 may affect concentrations of endocrine therapy and may be useful to personalize dosing and improve treatment outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP3ABreast NeoplasmsHumansFemaleAnastrozoleFulvestrantCytochrome P-450 CYP2C9NitrilesTriazolesEstradiolGenotypeAntineoplastic Agents, Hormonal

Stichwörter der Autor:innen

anastrozoledrug–drug interactionfulvestrantmetabolismpharmacogeneticspharmacokinetics

Substanzen

AnastrozoleFulvestrantCytochrome P-450 CYP2C9Cytochrome P-450 CYP3ANitrilesTriazolesEstradiolAntineoplastic Agents, HormonalCYP2C9 protein, humanCYP3A4 protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
  • Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA.
  • Western University/Canadian Cancer Trials Group, London, ON, N5X 3K8, Canada.
  • Loyola University Chicago Stritch School of Medicine, Maywood, IL 60153, USA.
  • Cancer Center of Kansas, Wichita, KS 67214, USA.
  • Kaiser Permanente, Beaverton, OR 97005, USA.

ORCID-Profile: Delaney V Rutherford, Sarah Medley, Nicholas C Henderson, Christina L Gersch, Ted A Vandenberg, Kathy S Albain, Shaker R Dakhil, Julie R Gralow, Gabriel N Hortobagyi, Lajos Pusztai, Daniel F Hayes, Kelley M Kidwell, N Lynn Henry, William E Barlow, James M Rae, Daniel L Hertz

Förderung

  • NCATS NIH HHS
  • NCI NIH HHS
  • American Association of Colleges of Pharmacy
  • Breast Cancer Research Foundation
  • National Cancer Institute
  • National Clinical Trials Network

Zitieren

APA

Rutherford, D. V., Medley, S., Henderson, N. C., Gersch, C. L., Vandenberg, T. A., Albain, K. S., Dakhil, S. R., Tirumali, N. R., Gralow, J. R., Hortobagyi, G. N., Pusztai, L., Mehta, R. S., Hayes, D. F., Kidwell, K. M., Henry, N. L., Barlow, W. E., Rae, J. M., & Hertz, D. L. (2023). Effects of CYP3A4 and CYP2C9 Genotype on Systemic Anastrozole and Fulvestrant Concentrations in SWOG S0226. Pharmacogenomics. https://doi.org/10.2217/pgs-2023-0097

Vancouver

Rutherford DV, Medley S, Henderson NC, Gersch CL, Vandenberg TA, Albain KS, et al. Effects of CYP3A4 and CYP2C9 Genotype on Systemic Anastrozole and Fulvestrant Concentrations in SWOG S0226. Pharmacogenomics. 2023. doi:10.2217/pgs-2023-0097

BibTeX
@article{Rutherford2023,
  author = {Rutherford, Delaney V and Medley, Sarah and Henderson, Nicholas C and Gersch, Christina L and Vandenberg, Ted A and Albain, Kathy S and Dakhil, Shaker R and Tirumali, Nagendra R and Gralow, Julie R and Hortobagyi, Gabriel N and Pusztai, Lajos and Mehta, Rita S and Hayes, Daniel F and Kidwell, Kelley M and Henry, N Lynn and Barlow, William E and Rae, James M and Hertz, Daniel L},
  title = {Effects of CYP3A4 and CYP2C9 Genotype on Systemic Anastrozole and Fulvestrant Concentrations in SWOG S0226},
  journal = {Pharmacogenomics},
  year = {2023},
  doi = {10.2217/pgs-2023-0097}
}
Kostenlos starten →